GUTS FRACTYL HEALTH, INC.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1572616 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY-22.5%
TTM net income YoY10.9%
TTM EPS YoY96.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin46.2%
Operating margin-100,571.0%
Net margin-73,864.5%
FCF margin-72,350.5%
EBITDA margin-99,843.0%
Returns
ROE—
ROA-74.6%
ROIC (approx.)—
Asset turnover0.00x
Leverage & solvency
Liabilities / assets73.7%
Debt / equity0.00x
Current ratio3.63x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.95x
Accruals ratio-3.4%
Payout ratio—
Capex / revenue1,897.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | $3,000 |
| Cost of revenue | — | — | — | — | — | — | — | $0 |
| Gross profit | — | — | — | — | — | — | — | $3,000 |
| R&D expense | $12.45M | $13.81M | $15.60M | $16.49M | $17.46M | $21.15M | $19.43M | $20.28M |
| SG&A expense | $6.20M | $5.28M | $5.22M | $6.79M | $5.24M | $4.93M | $5.32M | $4.93M |
| Operating income | -$18.65M | -$19.10M | -$20.82M | -$23.28M | -$22.69M | -$26.08M | -$24.76M | -$25.21M |
| Net income | -$14.15M | -$25.54M | $9.22M | -$43.73M | -$45.60M | -$27.89M | -$23.73M | -$24.97M |
| EBITDA | -$18.37M | -$18.82M | -$20.54M | -$23.00M | -$22.40M | -$25.81M | -$24.47M | -$24.99M |
| EPS (basic) | -1.07 | -0.16 | 0.06 | — | -8.46 | -0.57 | -0.49 | — |
| EPS (diluted) | -1.07 | -0.16 | 0.06 | — | -8.46 | -0.57 | -0.49 | — |
| Weighted avg. shares (diluted) | 13.25M | 158.65M | 158.49M | — | 5.39M | 49.04M | 48.87M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $31.52M | $47.14M | $63.17M | $81.54M | $81.91M | $26.55M | $46.36M | $71.72M |
| Receivables | — | — | — | — | — | — | — | $0 |
| Inventory | — | — | — | — | — | — | — | $73,000 |
| Current assets | $34.33M | $49.60M | $65.92M | $87.58M | $79.70M | $26.69M | $47.05M | $71.76M |
| PP&E, net | $1.69M | $1.85M | $2.13M | $2.41M | $2.68M | $2.96M | $3.14M | $2.98M |
| Total assets | $65.92M | $81.98M | $99.39M | $121.40M | $114.27M | $62.01M | $83.04M | $108.08M |
| Current liabilities | $17.34M | $15.74M | $15.41M | $18.33M | $18.68M | $21.83M | $18.80M | $19.77M |
| Total liabilities | $79.14M | $83.64M | $78.01M | $111.94M | $117.45M | $80.22M | $76.67M | $79.65M |
| Shareholders' equity | -$13.22M | -$1.67M | $21.38M | $9.46M | -$3.18M | -$18.21M | $6.38M | $28.42M |
| Shares outstanding | 13.26M | 158.65M | 158.65M | 12.78M | 132.22M | 49.92M | 48.92M | 48.76M |
| Cash flow statement | ||||||||
| Operating cash flow | -$15.71M | -$15.90M | -$22.48M | -$21.34M | -$22.71M | -$21.20M | -$25.08M | -$17.03M |
| Capital expenditure | — | — | — | $3,000 | $8,000 | $98,000 | $448,000 | $233,000 |
| Free cash flow | — | — | — | -$21.34M | -$22.72M | -$21.30M | -$25.53M | -$17.27M |
| Investing cash flow | — | — | — | -$3,000 | -$8,000 | -$98,000 | -$448,000 | -$233,000 |
| Financing cash flow | $83,000 | -$127,000 | $4.11M | $25.22M | $78.09M | $1.48M | $171,000 | $67,000 |
| Depreciation & amortization | $276,000 | $278,000 | $281,000 | $279,000 | $290,000 | $270,000 | $290,000 | $223,000 |
| Stock-based compensation | $2.39M | $2.50M | $2.53M | $1.85M | $1.64M | $1.78M | $1.41M | $2.90M |
Free plan shows the latest 8 periods; Pro shows all 15 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.